X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy.
Lead Product(s): Tirapazamine,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The proceeds from the financing will further advance clinical studies of the company’s lead candidate, TEC-001, a potential first-in-class therapeutic agent designed to induce tumor necrosis and enhance immune checkpoint inhibitors in solid cancers with liver metastasis.
Lead Product(s): TEC-001
Therapeutic Area: Oncology Product Name: TEC-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: W.T.T. Investment
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Financing February 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
